Source: PR NEWSWIRE

Press Release: VeroScience : VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) and Neurophysiological Investigations of Brain Dopamine Regulation of Metabolism with Eight Papers Presented at the 2015 American Diabetes Association Conference

TIVERTON, R.I., June 6, 2015 /PRNewswire/ -- VeroScience, Inc. is pleased to be participating at the American Diabetes Association's 75th Scientific Sessions in Boston, Mass with additional clinical data on circadian-timed morning administration of bromocriptine-QR (Cycloset), a...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
CEO Avatar

President

Anthony H. Cincotta

CEO Approval Rating

76/100

Read more